Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Original Article

B.E. Sands, L. Peyrin-Biroulet, E.V.L. Jr., Jr., S. Danese, J.-F. Colombel, M. Törüner, L. Jonaitis, B. Abhyankar, J. Chen, R. Rogers, R.A. Lirio, J.D. Bornstein, and S. Schreiber

N Engl J Med 2019;381:1215-1226

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
09/25/2019
Course expires: 
09/26/2021

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Sunday, September 26, 2021 - 11:59pm.